GI Innovation decides to register US patent for combination therapy including GI-101 and GI-102
(Provided by GI Innovation)
[이데일리 김진호 기자]GI Innovation (358570) announced on the 15th that an additional U.S. patent has been registered for anti-cancer combination therapy including ‘GI-101’ or ‘GI-102’ discovered by the company.
According to GI Innovation, this anticancer drug combination therapy patent involves the combination of GI-101 or GI-102 with anticancer drugs with various mechanisms, such as PARP inhibitors (olaparib, etc.), CDK4/6 inhibitors (abemaciclib, etc.), VEGFR inhibitors, and EGFR inhibitors. It contains exclusive rights regarding the therapy.
Previously, in May, the company used candidate substances such as GI-101 or GI-102 in combination with immunotherapy drugs such as ‘Keytruda’ (ingredient name: pembrolizumab) from Merck of the U.S. and ‘Tecentriq’ (ingredient name: atezolizumab) from Swiss Roche. Exclusive rights to the therapy have been secured through a U.S. patent.
Global pharmaceutical companies are expanding additional indications or combination therapies as part of an evergreening strategy to prevent the emergence of latecomers due to the expiration of patents for key substances in anticancer drugs they own. GI Innovation’s analysis is that the U.S. patents related to its materials registered this year can give strength to the evergreening strategy of existing agents.
In fact, the major substance patents for olaparib and abemaciclib included in this patent expire in the United States in 2028 and 2029, respectively. However, the patent period for the combination therapy of these substances and GI101 or GI102 is 2041.
Myeong-ho Jang, Chief Scientific Officer (CSO) of GI Innovation, said, “This U.S. patent registration corresponds to a combination therapy with blockbuster anticancer drugs whose patents are about to expire, so we have prepared sufficient value as a partner for combination use with various anticancer drugs depending on the clinical results.” He emphasized, “We will do our best to aim for technology transfer next year through close contact with global pharmaceutical companies.”
2023-11-15 01:19:35
#Innovation #decides #register #patent #combination #therapy #including #GI101 #GI102
